US20010002391A1 - Treatment of infarcts - Google Patents
Treatment of infarcts Download PDFInfo
- Publication number
- US20010002391A1 US20010002391A1 US09/285,170 US28517098A US2001002391A1 US 20010002391 A1 US20010002391 A1 US 20010002391A1 US 28517098 A US28517098 A US 28517098A US 2001002391 A1 US2001002391 A1 US 2001002391A1
- Authority
- US
- United States
- Prior art keywords
- activation
- proteasome
- inhibitor
- mammal
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention relates to treatment of ischemia and reperfusion injury, including preventing or reducing the size of infarct after vascular occlusion.
- Major ischemic events of therapeutic concern include, but are not limited to, heart attacks and stroke.
- stroke accounts for 10% of all premature deaths, and of those that survive the insult, 50% are left severely disabled. Only a small fraction, 10%, of patients actually recover full function.
- Reperfusion injury may occur as a result of one or more of the following events: cellular acidosis leading to calcium overload; increased intracellular osmotic loads of catabolites leading to cell swelling; free radicals from neutrophils and other inflammatory cells.
- Neutrophils are seen in reperfused myocardium shortly after reperfusion. Monocytes/macrophages appear within 24 to 48 hours. Neutrophil infiltration is three to five fold greater in reperfused myocardium than in ischemic myocardium, is initiated by adhesion to endothelial cells, and occurs within 10 minutes of reperfusion. Neutrophils in and of themselves may become trapped in capillaries and impede reperfusion. Intravascular neutrophils may block up to 27% of the capillaries, and have been shown to be related to decreased regional blood flow (Forman et al., Acute Myocardial Infarction, eds.Gersh et al. Elsevier: 1991, pp 347-370). This can result in the “no-reflow” phenomenon, where blood flow continues to decrease after reperfusion.
- neutrophils must first adhere themselves to the endothelial cell wall through the interactions with adhesion molecules. Once attached to the vessel cell wall, the neutrophils then force themselves between adjacent endothelial cells and move into the brain tissue, where they release cytotoxic cytokines. The expression of such adhesion molecules is increased following cell damage including ischemia. In addition, endothelial cell walls become more permeable to infiltrating cells due to the release of nitric oxide (NO). Agents that inhibit the movement (diapedesis) of neutrophils from surrounding blood vessels into the damaged tissue may thus be of value in allowing dying cells time to recover from the ischemic insult.
- NO nitric oxide
- the present invention is directed to a method of treating ischemia in a mammal comprising administering to said mammal an effective amount of an NF- ⁇ B activation inhibitor.
- Preferred NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- the agent is administered to the mammal after the onset of transient vascular occlusion and prior to induction of permanent ischemic damage.
- the present invention is directed to a method of preventing or lessening the severity reperfusion injury in a mammal comprising administering to said mammal an effective amount of an NF- ⁇ B activation inhibitor.
- Preferred NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- the present invention is directed to a method of preventing, reducing the size of, or lessening the severity of infarction in a mammal comprising administering to said mammal an effective amount of an NF- ⁇ B activation inhibitor.
- Preferred NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- the method according to this aspect of the invention prevents or lessens severity of infarction after occlusion of a cerebral vessel or a cardiac vessel.
- the method prevents the occlusion from resulting in stroke, or lessens the severity of a stroke resulting from cerebral vessel occlusion.
- the present invention is directed to a method of treating ischemia or reperfusion injury, including preventing or lessening the severity of infarction in a mammal comprising administering to the mammal an adjunct therapeutic, in addition to administering an NF- ⁇ B activation inhibitor.
- Preferred NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- adjunct therapeutics include without limitation, agents such as steroids which further inhibit NF- ⁇ B activation or inhibit the expression or action of proinflammatory cytokines or cellular adhesion molecules; agents which act to either reperfuse or oxygenate tissues, such antiedema drugs, thrombolytics such as TPA, streptokinase and urokinase, polyanions such as heparin, anticoagulants; and agents that assist in temperature normalization.
- NF- ⁇ B activation inhibitors inhibit NF- ⁇ B activation by the ubiquitin-proteasome pathway.
- the NF- ⁇ B activation inhibitor inhibits phosphorylation of I ⁇ B- ⁇ .
- the NF- ⁇ B activation inhibitor is a proteasome inhibitor.
- the proteasome inhibitor is selected from the group consisting of peptidyl aldehydes, boronic acids, boronic esters, lactacystin, and lactacystin analogs.
- NF- ⁇ B activation inhibitor is a ubiquitin pathway inhibitor.
- FIG. 1 shows the cascade of NF- ⁇ B activation leading to reperfusion injury, including infarct. Points of intervention by the methods according to the invention are indicated.
- FIG. 2 shows the ubiquitin-proteasome pathway.
- FIG. 3 is directed to reduction of infarct volume following middle cerebral artery (MCA) occlusion by administration of the proteasome inhibitor N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid.
- FIG. 4 is directed to reduction of infarct size, expressed as a percentage of the contralateral hemisphere, by administration of the proteasome inhibitor N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid.
- FIG. 5 is directed to reduction of infarct volume by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin ⁇ -lactone following middle cerebral artery (MCA) occlusion.
- FIG. 6 is directed to reduction of neurological score by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin ⁇ -lactone following middle cerebral artery (MCA) occlusion.
- FIG. 7 is directed to reduction of infarct volume by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin ⁇ -lactone.
- FIG. 8 is directed to reduction of neurological score by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin ⁇ -lactone.
- the invention relates to treatment of ischemia and reperfusion injury, including preventing, reducing the size or lessening the severity of infarct after vascular occlusion.
- the patent applications, patents and literature references cited herein indicate the knowledge in this field and are hereby incorporated by reference in their entirety. In the case of inconsistencies the present disclosure will prevail.
- the ubiquitin-proteasome pathway is a target for treating ischemia and reperfusion injury, including preventing, reducing the size, or lessening the severity of infarcts following vascular occlusions such as occur during heart attack or stroke, and that inhibitors of NF- ⁇ B activation via the ubiquitin-proteasome pathway can provide effective therapy for these conditions.
- the invention provides surprisingly effective methods for treating ischemia or reperfusion injury.
- the present inventors have discovered that blocking proteasome function reduces the effects of ischemia, such as reducing infarct size following vascular occlusion. This can be done by direct proteasome inhibition (shown with N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid and 7-n-propyl-clasto-lactacystin ⁇ -lactone) or by blocking ubiquitination of proteasome-targeted proteins such as I ⁇ B- ⁇ .
- Any inhibitors which affect activation of NF- ⁇ B via the ubiquitin/proteasome pathway in eukaryotic cells are expected to be effective in preventing or treating infarction, including infarction following vascular occlusion and are thus in the scope of the present invention.
- NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- the present invention is directed to a method of treating ischemia in a mammal comprising administering to said mammal an effective amount of an NF- ⁇ B activation inhibitor.
- All tissues are sensitive to lack of oxygen (ischemia) resulting from hypoperfusion.
- Major ischemic events of therapeutic concern include, but are not limited to, heart attacks and stroke.
- Ischemia also can affect other tissues, including retinal, liver, kidney, bone, placental and spinal tissue.
- Prolonged ischemia results in cellular damage, manifest, in the case of cerebral ischemia, as neurological dysfunction.
- Agents currently used in treatment of stroke are targeted at 1) reversing excessive excitotoxic phenomena associated with an ischemic episode; or 2) increasing blood flow to ischemic tissue.
- Ischemic injury may commonly result from e.g., vascular occlusion such as by an embolus or thrombus, hemorrhage, near drowning and near suffocation.
- vascular occlusion such as by an embolus or thrombus, hemorrhage, near drowning and near suffocation.
- ischemia causes a massive release of the excitotoxic amino acid, glutamate, from presynaptic nerve endings in the brain which act on N-methyl-D-aspartate (NMDA) receptors on adjacent cells. Once activated, NMDA receptors allow excessive calcium to enter the cell, which in turn activates a number of secondary pathways that ultimately lead to cellular protein degradation and cell death.
- NMDA N-methyl-D-aspartate
- TPA tissue plasminogen activator
- TPA While effective to a limited extent in stroke patients, by actually promoting bleeding, drugs like TPA can be lethal to those patients that have cerebral hemorrhage. As such, TPA cannot be given until the patient has been confirmed as having a stroke rather than hemorrhage. For a stroke patient, the time taken for this analysis to occur obviously increases the length of time of the ischemia and hence the amount of salvageable tissue is reduced. Agents such as NF- ⁇ B activation inhibitors that can act on the ischemic cascade system itself are not limited by such a prolonged diagnosis period, as they are not detrimental in cerebral hemorrhage patients.
- Preferred NF- ⁇ B activation inhibitors inhibit NF- ⁇ B activation by the ubiquitin-proteasome pathway.
- the NF- ⁇ B activation inhibitor inhibits phosphorylation of I ⁇ B- ⁇ .
- the NF- ⁇ B activation inhibitor is a proteasome inhibitor.
- the inhibition of the proteasome is preferably less than complete inhibition.
- the proteasome inhibitor is selected from the group consisting of peptidyl aldehydes, boronic acids, boronic esters, lactacystin, and lactacystin analogs.
- the NF- ⁇ B activation inhibitor is a ubiquitin pathway inhibitor.
- the transcription factor NF- ⁇ B is a member of the Rel protein family.
- the Rel family of transcriptional activator proteins can be divided into two groups. The first group requires proteolytic processing, and includes p105 and p100, which are processed to p50 and p52, respectively. The second group does not require proteolytic processing and includes p65 (Rel A), Rel (c-Rel), and Rel B.
- NF- ⁇ B comprises two subunits, p50 and an additional member of the Rel gene family, e.g., p 65. Unprocessed p105 can also associate with p65 and other members of the Rel family.
- the p50-p65 heterodimer is present in an inactive form in the cytoplasm, bound to I ⁇ B- ⁇ .
- the ternary complex can be activated by the dissociation and destruction of I ⁇ B- ⁇ , while the p65/p 105 heterodimer can be activated by processing of p 105.
- the ubiquitin-proteasome pathway plays an essential role in the regulation of NF- ⁇ B activity, being responsible both for processing of p105 to p50 and for the degradation of the inhibitor protein I ⁇ B- ⁇ .
- I ⁇ B- ⁇ In order to be targeted for degradation by the proteasome, I ⁇ B- ⁇ must first undergo selective phosphorylation at serine residues 32 and 36, followed by ubiquitination.
- NF- ⁇ B translocates to the nucleus, where it plays a central role in the regulation of a remarkably diverse set of genes involved in the immune and inflammatory responses (Grilli et al., International Review of Cytology 143:1-62 (1993)).
- NF- ⁇ B is required for the expression of a number of genes involved in the inflammatory response, such as TNF- ⁇ gene and genes encoding the cell adhesion molecules E-selectin, P-selectin, ICAM, and VCAM (Collins, T., Lab. Invest. (1993) 68:499.
- NF- ⁇ B is also required for the expression of a large number of cytokine genes such as IL-2, IL-6, granulocyte colony stimulating factor, and IFN- ⁇ .
- Inducible nitric oxide synthetase is also under regulatory control of NF- ⁇ B.
- Proteasome inhibitors block I ⁇ B- ⁇ degradation and activation of NF- ⁇ B (Palombella et al WO 95/25533 published Sep. 28, 1995; Traenckner, et al., EMBO J. (1994) 13:5433).
- Proteasome inhibitors also block TNF- ⁇ induced expression of the leukocyte adhesion molecules E-selectin, VCAM-1, and ICAM-1 (Read, et al., Immunity (1995) 2:493).
- E-selectin the leukocyte adhesion molecules
- VCAM-1 a cell adhesion molecules
- ICAM-1 ICAM-1
- These cell adhesion molecules play a critical role in supporting the emigration of leukocytes from the bloodstream to extravascular sites of injury such as ischemic tissue.
- the resultant influx of cells particularly neutrophils, can promote damage by release of cytokines that speed cell death and signal additional cells (e.g., macrophages) to invade the area
- the present invention is directed to a method of preventing or lessening the severity of reperfusion injury in a mammal comprising administering to said mammal an effective amount of an NF- ⁇ B activation inhibitor.
- Reperfusion injury may occur as a result of one or more of the following events: cellular acidosis leading to calcium overload; increased intracellular osmotic loads of catabolites leading to cell swelling; free radicals from neutrophils and other inflammatory cells.
- Preferred NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- the present invention is directed to a method of preventing, reducing the size of, or lessening the severity of infarction in a mammal comprising administering to said mammal an effective amount of an NF- ⁇ B activation inhibitor.
- Preferred NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- the method according to this aspect of the invention prevents, reduces the size or lessens the severity of infarction after occlusion of a cerebral vessel or a cardiac vessel.
- the method prevents the occlusion from resulting in stroke, or lessens the severity of a stroke resulting from cerebral vessel occlusion.
- thrombotic stroke where occlusion of cerebral blood vessels is believed to be caused by a plug of aggregated platelets. Often, these platelet plugs are released as emboli from platelet thrombi on atherosclerotic plaques in major carotid or cerebral vessels. Thrombotic strokes often have a characteristic “stuttering” onset in which an initial modest, often reversible, neurological deficit is followed by a more severe, irreversible stroke. The initial event often reflects transient cerebrovascular obstruction by platelet thrombi, which is potentially reversible.
- a mild stroke can be viewed as the extreme end of the spectrum of transient ischemic attacks (TIA)—a reversible neurological deficit in which a cerebral vessel is transiently occluded by an embolic platelet thrombus, which subsequently disaggregates, thus allowing flow to be reestablished. Therefore, the administration of an agent as disclosed herein after the onset of transient vascular occlusion is contemplated by the present invention.
- Another important form of stroke is stroke after cerebral hemmorhage, as discussed above.
- the agents disclosed herein will have broad range efficacy in preventing, reducing the size, or lessening the severity of infarcts resulting from a variety of causes, including thrombotic stroke and stroke following cerebral hemmorhage.
- the reduction of infarct size or lessening of infarct severity will be inferred from a reduction in symptoms associated with the infarct, including without limitation neurological symptoms and cardiac performance symptoms.
- the present invention is directed to a method to treating ischemia or reperfusion injury, including without limitation reducing the size or lessening the severity of infarction in a mammal comprising administering to the mammal an adjunct therapeutic, in addition to administering an NF- ⁇ B activation inhibitor.
- Preferred NF- ⁇ B activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of I ⁇ B- ⁇ . and mixtures thereof.
- adjunct therapeutics include without limitation, agents which such as steroids which further inhibit NF- ⁇ B activation or inhibit the expression or action of proinflammatory cytokines or cellular adhesion molecules; agents which act to either reperfuse or oxygenate tissues, antiedema drugs, thrombolytics such as TPA, streptokinase and urokinase, polyanions such as heparin, anticoagulants; and agents that assist in temperature normalization.
- Agents that inhibit the action of cytokines or cellular adhesion molecules include, without limitation, antibodies, or an antibody derivative, which may more preferably be a monoclonal antibody, a human antibody, a humanized antibody, a single-chain antibody, a chimeric antibody, or an antigen-binding antibody fragment.
- antibodies, or an antibody derivative which may more preferably be a monoclonal antibody, a human antibody, a humanized antibody, a single-chain antibody, a chimeric antibody, or an antigen-binding antibody fragment.
- the use of any of the agents discussed or disclosed herein in combination with any other agent or agents used in the treatment of stroke or myocardial infarction is further contemplated within the scope of the present invention.
- Treatment shall mean preventing or lessening ischemic injury or reperfusion injury, including the prevention of infarction or reduction in size or lessening in severity of infarct, including without limitation infarct after vascular occlusion. Any amelioration of any symptom of the infarct pursuant to treatment using any proteasome inhibitor, ubiquitin pathway inhibitor, or agent that interferes with activation of NF- ⁇ B via the ubiquitin proteasome pathway is within the scope of the invention.
- mammals is intended to include humans.
- “Inhibitors of NF- ⁇ B activation” or “NF- ⁇ B activation inhibitors” shall mean any substance which inhibits of NF- ⁇ B activation via the ubiquitin proteasome pathway, and shall include any substance that 1) inhibits the proteasome or the activity thereof; 2) inhibits ubiquitination of I ⁇ B- ⁇ or p105; or 3) inhibits phosphorylation of I ⁇ B- ⁇ or p105.
- Ubiquitin pathway inhibitor shall mean any substance which directly or indirectly inhibits ubiquitination or the transfer of ubiquitin to proteins.
- Non-limiting examples of ubiquitin pathway inhibitors include those disclosed in Berleth et al, Biochem. 35(5):1664-1671, (1996). Inhibitors of I ⁇ B- ⁇ phosphorylation are also known (Chen, Cell 84:853 (1996)).
- proteasome inhibitor shall mean any substance which directly or indirectly inhibits the proteasome or the activity thereof.
- Non-limiting examples of proteasome inhibitors for use in the present invention include peptide aldehydes (Stein et al. WO 95/24914 published Sep. 21, 1995; Siman et al. WO 91/13904 published Sep. 19, 1991; Iqbal et al. J. Med. Chem. 38:2276-2277 (1995)), peptide boronic acids (Adams et al. WO 96/13266 published May 9, 1996 ; Siman et al. WO 91/13904), lactacystin, and lactacystin analogs (Fenteany et al. Proc. Natl. Acad. Sci. USA (1994) 91:3358; Fenteany et al. WO 96/32105, published Oct. 17, 1996).
- Peptide aldehyde proteasome inhibitors for use in the present invention preferably are those disclosed in Stein et al. WO 95/24914 published Sep. 21, 1995 or Siman et al. WO 91/13904 published Sep. 19, 1991, both hereby incorporated by reference in their entirety.
- Boronic acid or ester compounds for use in the present invention preferably are those disclosed in Adams et al. WO 96/13266 published May 9, 1996, or Siman et al. WO 91/13904, both of which are hereby incorporated by reference in their entirety.
- the boronic acid compound for use in the present invention is selected from the group consisting of:
- N-(4-morpholine)carbonyl-[O-(2-pyridylmethyl)]-L-tyrosine-L-leucine boronic acid [0050] N-(4-morpholine)carbonyl-[O-(2-pyridylmethyl)]-L-tyrosine-L-leucine boronic acid.
- Lactacystin and lactacystin analog compounds for use in the present invention preferably are those disclosed in Fenteany et al. WO 96/32105, published Oct. 17, 1996, hereby incorporated by reference in its entirety. More preferably, the lactacystin analog is selected from lactacystin, clasto-lactacystin ⁇ -lactone, 7-ethyl-clasto-lactacystin ⁇ -lactone and 7-n-propyl-clasto-lactacystin ⁇ -lactone are used for the methods of the invention. Most preferably the lactacystin analog is 7-n-propyl-clasto-lactacystin ⁇ -lactone.
- the agents disclosed herein may be administered by any route, including intradermally, subcutaneously, orally, intraarterially or intravenously. Preferably, administration will be by the intravenous route. Preferably parenteral administration may be provided in a bolus or by infusion.
- the concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration.
- Effective amounts of agents for treating ischemia or reperfusion injury would broadly range between about 10 ⁇ g and about 50 mg per Kg of body weight of a recipient mammal.
- the agent may be administered in a single dose or in repeat doses. Treatments may be administered daily or more frequently depending upon a number of factors, including the overall health of a patient, and the formulation and route of administration of the selected compound(s).
- the disclosed compound may be administered at any time before, during, or after the onset of ischemia.
- the agent is administered after the onset of ischemia, but at a time early enough to reverse damage to some or all of the affected tissue.
- the agent is administered less than 12 hours, more preferably less than 6 hours and still more preferably less than about 3 hours after onset of the ischemic event.
- Treatment may be initiated before, during or after reperfusion of the ischemic tissue. In many instances, the time of reperfusion cannot be accurately determined, but it is preferred that treatment begin before, during or soon after reperfusion to prevent or lessen additional damaging consequences which may result from reperfusion.
- drugs such as TPA which break up the clot can be administered to reduce the potential tissue damage. Once dosed, the drug acts quickly to remove the vascular blockade and, therefore, the time at which the ischemic event ends can be determined.
- the inhibitor of NF- ⁇ B activation is administered at the same time or immediately following the clot dissolving drug.
- the inhibitor of NF- ⁇ B activation is administered prior to the onset of ischemia.
- the onset of ischemia can be predicted in the case of certain medical procedures, such as surgical procedures.
- the disclosed compound is administered just prior to or immediately following the release of ischemia and onset of reperfusion during such a medical procedure (e.g., angioplasty procedures).
- TTC triphenyltetrazolium chloride
- the infarct was also expressed as a percentage of the contralateral (non-infarcted) hemisphere to provide an indication of how much of the ipsilateral (infarcted) hemisphere was actually damaged by the procedure. Because edema is present in the infarcted hemisphere, it is often impossible to directly ascertain the percentage of the ipsilateral hemisphere that has been damaged.
- Infarct volume was decreased by 62% on the ipsilateral hemisphere in treated animals (FIG. 1). This reflects a decrease in total damage of the hemisphere from 19% to 2% (FIG. 2).
- TTC triphenyltetrazolium chloride
- TTC triphenyltetrazolium chloride
- Two additional groups of rats were given iv bolus injections (1.0 mL/kg) of 7-n-propyl-clasto-lactacystin ⁇ -lactone at 0 minutes, 2 hours, and 6 hours after the start of the occlusion.
- infarct volume was decreased by 50% (FIG. 3). Infarct volume was not significantly decreased in either the 0.1 mg/kg ⁇ 3 dosage group or the 0.3 mg/kg ⁇ 3 dosage group (FIG. 7).
Abstract
Description
- This application is a continuation-in-part of U.S. application Ser. No. 08/988,339, filed Dec. 3, 1997 which is a continuation-in-part of U.S. application Ser. No. 08/801,936, filed Feb. 15, 1997.
- This invention relates to treatment of ischemia and reperfusion injury, including preventing or reducing the size of infarct after vascular occlusion.
- All tissues are sensitive to hypoperfusion and the resulting lack of oxygen, ischemia. Prolonged ischemia will result in cellular damage. The magnitude of the injury and the potential for tissue rescue depends upon the degree and duration of the ischemia. With long ischemic periods, cellular death occurs (infarction) and under these conditions the injury is irreversible. On the other hand, dying cells or cells targeted for cell death may be rescued by drug treatment, if applied in a timely fashion.
- Major ischemic events of therapeutic concern include, but are not limited to, heart attacks and stroke. In man, stroke accounts for 10% of all premature deaths, and of those that survive the insult, 50% are left severely disabled. Only a small fraction, 10%, of patients actually recover full function.
- Over 1,500,000 Americans suffer from myocardial infarctions each year. About half of these do not survive to reach the hospital. However, with the acceptance of thrombolytic therapy such as streptokinase or tissue plasminogen activator (TPA), the one month survival rate for patients who do reach the hospital is as high as 93.6% (Werns, S. W.Textbook of Interventional Cardiology, ed. Topol, E. J. WB Saunders: 1994, pp.142-153). By lysing the clot early in the course of infarct, ischemic muscle and tissue can be salvaged. However, reperfusion in and of itself leads to tissue damage.
- Reperfusion injury may occur as a result of one or more of the following events: cellular acidosis leading to calcium overload; increased intracellular osmotic loads of catabolites leading to cell swelling; free radicals from neutrophils and other inflammatory cells.
- Neutrophils are seen in reperfused myocardium shortly after reperfusion. Monocytes/macrophages appear within 24 to 48 hours. Neutrophil infiltration is three to five fold greater in reperfused myocardium than in ischemic myocardium, is initiated by adhesion to endothelial cells, and occurs within 10 minutes of reperfusion. Neutrophils in and of themselves may become trapped in capillaries and impede reperfusion. Intravascular neutrophils may block up to 27% of the capillaries, and have been shown to be related to decreased regional blood flow (Forman et al.,Acute Myocardial Infarction, eds.Gersh et al. Elsevier: 1991, pp 347-370). This can result in the “no-reflow” phenomenon, where blood flow continues to decrease after reperfusion.
- It is known that neutrophils must first adhere themselves to the endothelial cell wall through the interactions with adhesion molecules. Once attached to the vessel cell wall, the neutrophils then force themselves between adjacent endothelial cells and move into the brain tissue, where they release cytotoxic cytokines. The expression of such adhesion molecules is increased following cell damage including ischemia. In addition, endothelial cell walls become more permeable to infiltrating cells due to the release of nitric oxide (NO). Agents that inhibit the movement (diapedesis) of neutrophils from surrounding blood vessels into the damaged tissue may thus be of value in allowing dying cells time to recover from the ischemic insult.
- There is a need in the art for effective therapies to prevent or reduce the consequences of ischemia.
- In a first aspect, the present invention is directed to a method of treating ischemia in a mammal comprising administering to said mammal an effective amount of an NF-κB activation inhibitor. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof. Preferably, the agent is administered to the mammal after the onset of transient vascular occlusion and prior to induction of permanent ischemic damage.
- In a second aspect, the present invention is directed to a method of preventing or lessening the severity reperfusion injury in a mammal comprising administering to said mammal an effective amount of an NF-κB activation inhibitor. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof.
- In a third aspect, the present invention is directed to a method of preventing, reducing the size of, or lessening the severity of infarction in a mammal comprising administering to said mammal an effective amount of an NF-κB activation inhibitor. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof. In preferred embodiments, the method according to this aspect of the invention prevents or lessens severity of infarction after occlusion of a cerebral vessel or a cardiac vessel. In certain preferred embodiments, the method prevents the occlusion from resulting in stroke, or lessens the severity of a stroke resulting from cerebral vessel occlusion.
- In a fourth aspect, the present invention is directed to a method of treating ischemia or reperfusion injury, including preventing or lessening the severity of infarction in a mammal comprising administering to the mammal an adjunct therapeutic, in addition to administering an NF-κB activation inhibitor. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof. Certain preferred adjunct therapeutics include without limitation, agents such as steroids which further inhibit NF-κB activation or inhibit the expression or action of proinflammatory cytokines or cellular adhesion molecules; agents which act to either reperfuse or oxygenate tissues, such antiedema drugs, thrombolytics such as TPA, streptokinase and urokinase, polyanions such as heparin, anticoagulants; and agents that assist in temperature normalization.
- Preferred NF-κB activation inhibitors inhibit NF-κB activation by the ubiquitin-proteasome pathway. In certain preferred embodiments, the NF-κB activation inhibitor inhibits phosphorylation of IκB-α. In certain preferred embodiments, the NF-κB activation inhibitor is a proteasome inhibitor. Preferably, the proteasome inhibitor is selected from the group consisting of peptidyl aldehydes, boronic acids, boronic esters, lactacystin, and lactacystin analogs. In certain preferred embodiments, NF-κB activation inhibitor is a ubiquitin pathway inhibitor.
- FIG. 1 shows the cascade of NF-κB activation leading to reperfusion injury, including infarct. Points of intervention by the methods according to the invention are indicated.
- FIG. 2 shows the ubiquitin-proteasome pathway.
- FIG. 3 is directed to reduction of infarct volume following middle cerebral artery (MCA) occlusion by administration of the proteasome inhibitor N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid.
- FIG. 4 is directed to reduction of infarct size, expressed as a percentage of the contralateral hemisphere, by administration of the proteasome inhibitor N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid.
- FIG. 5 is directed to reduction of infarct volume by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin β-lactone following middle cerebral artery (MCA) occlusion.
- FIG. 6 is directed to reduction of neurological score by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin β-lactone following middle cerebral artery (MCA) occlusion.
- FIG. 7 is directed to reduction of infarct volume by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin β-lactone.
- FIG. 8 is directed to reduction of neurological score by administration of the proteasome inhibitor 7-n-propyl-clasto-lactacystin β-lactone.
- The invention relates to treatment of ischemia and reperfusion injury, including preventing, reducing the size or lessening the severity of infarct after vascular occlusion. The patent applications, patents and literature references cited herein indicate the knowledge in this field and are hereby incorporated by reference in their entirety. In the case of inconsistencies the present disclosure will prevail.
- It has now been unexpectedly discovered that the ubiquitin-proteasome pathway is a target for treating ischemia and reperfusion injury, including preventing, reducing the size, or lessening the severity of infarcts following vascular occlusions such as occur during heart attack or stroke, and that inhibitors of NF-κB activation via the ubiquitin-proteasome pathway can provide effective therapy for these conditions. The invention provides surprisingly effective methods for treating ischemia or reperfusion injury.
- The present inventors have discovered that blocking proteasome function reduces the effects of ischemia, such as reducing infarct size following vascular occlusion. This can be done by direct proteasome inhibition (shown with N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid and 7-n-propyl-clasto-lactacystin β-lactone) or by blocking ubiquitination of proteasome-targeted proteins such as IκB-α. Any inhibitors which affect activation of NF-κB via the ubiquitin/proteasome pathway in eukaryotic cells are expected to be effective in preventing or treating infarction, including infarction following vascular occlusion and are thus in the scope of the present invention.
- In accordance with the present invention, treatment of ischemia, including reperfusion injury, prevention of infarction and reduction in size or lessening of severity of infarct is achieved by administering to a mammal an effective amount of an NF-κB activation inhibitor. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof.
- In a first aspect, the present invention is directed to a method of treating ischemia in a mammal comprising administering to said mammal an effective amount of an NF-κB activation inhibitor. All tissues are sensitive to lack of oxygen (ischemia) resulting from hypoperfusion. Major ischemic events of therapeutic concern include, but are not limited to, heart attacks and stroke. Ischemia also can affect other tissues, including retinal, liver, kidney, bone, placental and spinal tissue. Prolonged ischemia results in cellular damage, manifest, in the case of cerebral ischemia, as neurological dysfunction. Agents currently used in treatment of stroke are targeted at 1) reversing excessive excitotoxic phenomena associated with an ischemic episode; or 2) increasing blood flow to ischemic tissue.
- Ischemic injury may commonly result from e.g., vascular occlusion such as by an embolus or thrombus, hemorrhage, near drowning and near suffocation. Without wishing to be bound by theory, it is believed that ischemia causes a massive release of the excitotoxic amino acid, glutamate, from presynaptic nerve endings in the brain which act on N-methyl-D-aspartate (NMDA) receptors on adjacent cells. Once activated, NMDA receptors allow excessive calcium to enter the cell, which in turn activates a number of secondary pathways that ultimately lead to cellular protein degradation and cell death. In the search for effective therapies, efforts have been made to target either the release of presynaptic glutamate (via K-opiate receptor stimulation), or blockade of NMDA receptor activation (either directly, with NMDA antagonists, or indirectly, with glycine antagonists). Calcium channel blockers and calpain inhibitors have also been investigated. While individual drugs have shown activity in both preclinical and clinical situations, the benefit is limited due to the speed at which the cascade occurs, the time taken for the drugs to be given, and the effectiveness of the therapy. The only drug used clinically to increase blood flow is tissue plasminogen activator (TPA), which aids in the rapid solubilization of clots that are responsible for the vessel blockade. While effective to a limited extent in stroke patients, by actually promoting bleeding, drugs like TPA can be lethal to those patients that have cerebral hemorrhage. As such, TPA cannot be given until the patient has been confirmed as having a stroke rather than hemorrhage. For a stroke patient, the time taken for this analysis to occur obviously increases the length of time of the ischemia and hence the amount of salvageable tissue is reduced. Agents such as NF-κB activation inhibitors that can act on the ischemic cascade system itself are not limited by such a prolonged diagnosis period, as they are not detrimental in cerebral hemorrhage patients.
- Preferred NF-κB activation inhibitors inhibit NF-κB activation by the ubiquitin-proteasome pathway. In certain preferred embodiments, the NF-κB activation inhibitor inhibits phosphorylation of IκB-α. In certain preferred embodiments, the NF-κB activation inhibitor is a proteasome inhibitor. In such embodiments the inhibition of the proteasome is preferably less than complete inhibition. Preferably, the proteasome inhibitor is selected from the group consisting of peptidyl aldehydes, boronic acids, boronic esters, lactacystin, and lactacystin analogs. In certain preferred embodiments, the NF-κB activation inhibitor is a ubiquitin pathway inhibitor.
- The transcription factor NF-κB is a member of the Rel protein family. The Rel family of transcriptional activator proteins can be divided into two groups. The first group requires proteolytic processing, and includes p105 and p100, which are processed to p50 and p52, respectively. The second group does not require proteolytic processing and includes p65 (Rel A), Rel (c-Rel), and Rel B. NF-κB comprises two subunits, p50 and an additional member of the Rel gene family, e.g., p 65. Unprocessed p105 can also associate with p65 and other members of the Rel family. In most cells, the p50-p65 heterodimer is present in an inactive form in the cytoplasm, bound to IκB-α. The ternary complex can be activated by the dissociation and destruction of IκB-α, while the p65/
p 105 heterodimer can be activated by processing ofp 105. - The ubiquitin-proteasome pathway plays an essential role in the regulation of NF-κB activity, being responsible both for processing of p105 to p50 and for the degradation of the inhibitor protein IκB-α. (Palombella et al., WO95/25533) In order to be targeted for degradation by the proteasome, IκB-α must first undergo selective phosphorylation at serine residues 32 and 36, followed by ubiquitination. (Alkalay et al., Proc. Natl. Acad. Sci. USA 92: 10599 (1995); Chen, WO97/35014)
- Once activated, NF-κB translocates to the nucleus, where it plays a central role in the regulation of a remarkably diverse set of genes involved in the immune and inflammatory responses (Grilli et al.,International Review of Cytology 143:1-62 (1993)). For example, NF-κB is required for the expression of a number of genes involved in the inflammatory response, such as TNF-α gene and genes encoding the cell adhesion molecules E-selectin, P-selectin, ICAM, and VCAM (Collins, T., Lab. Invest. (1993) 68:499. NF-κB is also required for the expression of a large number of cytokine genes such as IL-2, IL-6, granulocyte colony stimulating factor, and IFN-β. Inducible nitric oxide synthetase is also under regulatory control of NF-κB.
- Proteasome inhibitors block IκB-α degradation and activation of NF-κB (Palombella et al WO 95/25533 published Sep. 28, 1995; Traenckner, et al.,EMBO J. (1994) 13:5433). Proteasome inhibitors also block TNF-α induced expression of the leukocyte adhesion molecules E-selectin, VCAM-1, and ICAM-1 (Read, et al., Immunity (1995) 2:493). These cell adhesion molecules play a critical role in supporting the emigration of leukocytes from the bloodstream to extravascular sites of injury such as ischemic tissue. Although intended to serve a repair function, the resultant influx of cells, particularly neutrophils, can promote damage by release of cytokines that speed cell death and signal additional cells (e.g., macrophages) to invade the area.
- In a second aspect, the present invention is directed to a method of preventing or lessening the severity of reperfusion injury in a mammal comprising administering to said mammal an effective amount of an NF-κB activation inhibitor. Reperfusion injury may occur as a result of one or more of the following events: cellular acidosis leading to calcium overload; increased intracellular osmotic loads of catabolites leading to cell swelling; free radicals from neutrophils and other inflammatory cells. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof.
- In a third aspect, the present invention is directed to a method of preventing, reducing the size of, or lessening the severity of infarction in a mammal comprising administering to said mammal an effective amount of an NF-κB activation inhibitor. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof. In preferred embodiments, the method according to this aspect of the invention prevents, reduces the size or lessens the severity of infarction after occlusion of a cerebral vessel or a cardiac vessel. In certain preferred embodiments, the method prevents the occlusion from resulting in stroke, or lessens the severity of a stroke resulting from cerebral vessel occlusion.
- The most common form of stroke is thrombotic stroke, where occlusion of cerebral blood vessels is believed to be caused by a plug of aggregated platelets. Often, these platelet plugs are released as emboli from platelet thrombi on atherosclerotic plaques in major carotid or cerebral vessels. Thrombotic strokes often have a characteristic “stuttering” onset in which an initial modest, often reversible, neurological deficit is followed by a more severe, irreversible stroke. The initial event often reflects transient cerebrovascular obstruction by platelet thrombi, which is potentially reversible. Indeed, clinically, a mild stroke can be viewed as the extreme end of the spectrum of transient ischemic attacks (TIA)—a reversible neurological deficit in which a cerebral vessel is transiently occluded by an embolic platelet thrombus, which subsequently disaggregates, thus allowing flow to be reestablished. Therefore, the administration of an agent as disclosed herein after the onset of transient vascular occlusion is contemplated by the present invention. Another important form of stroke is stroke after cerebral hemmorhage, as discussed above. It is believed that the agents disclosed herein will have broad range efficacy in preventing, reducing the size, or lessening the severity of infarcts resulting from a variety of causes, including thrombotic stroke and stroke following cerebral hemmorhage. As a practical matter, the reduction of infarct size or lessening of infarct severity will be inferred from a reduction in symptoms associated with the infarct, including without limitation neurological symptoms and cardiac performance symptoms.
- In a fourth aspect, the present invention is directed to a method to treating ischemia or reperfusion injury, including without limitation reducing the size or lessening the severity of infarction in a mammal comprising administering to the mammal an adjunct therapeutic, in addition to administering an NF-κB activation inhibitor. Preferred NF-κB activation inhibitors are selected from the group consisting of proteasome inhibitors, ubiquitin pathway inhibitors, inhibitors of serine phosphorylation of IκB-α. and mixtures thereof. Certain preferred adjunct therapeutics include without limitation, agents which such as steroids which further inhibit NF-κB activation or inhibit the expression or action of proinflammatory cytokines or cellular adhesion molecules; agents which act to either reperfuse or oxygenate tissues, antiedema drugs, thrombolytics such as TPA, streptokinase and urokinase, polyanions such as heparin, anticoagulants; and agents that assist in temperature normalization. Agents that inhibit the action of cytokines or cellular adhesion molecules include, without limitation, antibodies, or an antibody derivative, which may more preferably be a monoclonal antibody, a human antibody, a humanized antibody, a single-chain antibody, a chimeric antibody, or an antigen-binding antibody fragment. The use of any of the agents discussed or disclosed herein in combination with any other agent or agents used in the treatment of stroke or myocardial infarction is further contemplated within the scope of the present invention.
- In the present description, the following definitions will be used.
- “Treatment” shall mean preventing or lessening ischemic injury or reperfusion injury, including the prevention of infarction or reduction in size or lessening in severity of infarct, including without limitation infarct after vascular occlusion. Any amelioration of any symptom of the infarct pursuant to treatment using any proteasome inhibitor, ubiquitin pathway inhibitor, or agent that interferes with activation of NF-κB via the ubiquitin proteasome pathway is within the scope of the invention.
- The term “mammals” is intended to include humans.
- “Inhibitors of NF-κB activation” or “NF-κB activation inhibitors” shall mean any substance which inhibits of NF-κB activation via the ubiquitin proteasome pathway, and shall include any substance that 1) inhibits the proteasome or the activity thereof; 2) inhibits ubiquitination of IκB-α or p105; or 3) inhibits phosphorylation of IκB-α or p105.
- “Ubiquitin pathway inhibitor” shall mean any substance which directly or indirectly inhibits ubiquitination or the transfer of ubiquitin to proteins. Non-limiting examples of ubiquitin pathway inhibitors include those disclosed in Berleth et al,Biochem. 35(5):1664-1671, (1996). Inhibitors of IκB-α phosphorylation are also known (Chen, Cell 84:853 (1996)).
- “Proteasome inhibitor” shall mean any substance which directly or indirectly inhibits the proteasome or the activity thereof. Non-limiting examples of proteasome inhibitors for use in the present invention include peptide aldehydes (Stein et al. WO 95/24914 published Sep. 21, 1995; Siman et al. WO 91/13904 published Sep. 19, 1991; Iqbal et al.J. Med. Chem. 38:2276-2277 (1995)), peptide boronic acids (Adams et al. WO 96/13266 published May 9, 1996; Siman et al. WO 91/13904), lactacystin, and lactacystin analogs (Fenteany et al. Proc. Natl. Acad. Sci. USA (1994) 91:3358; Fenteany et al. WO 96/32105, published Oct. 17, 1996).
- Peptide aldehyde proteasome inhibitors for use in the present invention preferably are those disclosed in Stein et al. WO 95/24914 published Sep. 21, 1995 or Siman et al. WO 91/13904 published Sep. 19, 1991, both hereby incorporated by reference in their entirety.
- Boronic acid or ester compounds for use in the present invention preferably are those disclosed in Adams et al. WO 96/13266 published May 9, 1996, or Siman et al. WO 91/13904, both of which are hereby incorporated by reference in their entirety.
- More preferably, the boronic acid compound for use in the present invention is selected from the group consisting of:
- N-(4-morpholine)carbonyl-β-(1-naphthyl)-L-alanine-L-leucine boronic acid
- N-(8-quinoline)sulfonyl-β-(1-naphthyl)-L-alanine-L-alanine-L-leucine boronic acid,
- N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid, and
- N-(4-morpholine)carbonyl-[O-(2-pyridylmethyl)]-L-tyrosine-L-leucine boronic acid.
- Lactacystin and lactacystin analog compounds for use in the present invention preferably are those disclosed in Fenteany et al. WO 96/32105, published Oct. 17, 1996, hereby incorporated by reference in its entirety. More preferably, the lactacystin analog is selected from lactacystin, clasto-lactacystin β-lactone, 7-ethyl-clasto-lactacystin β-lactone and 7-n-propyl-clasto-lactacystin β-lactone are used for the methods of the invention. Most preferably the lactacystin analog is 7-n-propyl-clasto-lactacystin β-lactone.
- The agents disclosed herein may be administered by any route, including intradermally, subcutaneously, orally, intraarterially or intravenously. Preferably, administration will be by the intravenous route. Preferably parenteral administration may be provided in a bolus or by infusion.
- The concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. Effective amounts of agents for treating ischemia or reperfusion injury would broadly range between about 10 μg and about 50 mg per Kg of body weight of a recipient mammal. The agent may be administered in a single dose or in repeat doses. Treatments may be administered daily or more frequently depending upon a number of factors, including the overall health of a patient, and the formulation and route of administration of the selected compound(s).
- The disclosed compound may be administered at any time before, during, or after the onset of ischemia. In certain preferred embodiments, the agent is administered after the onset of ischemia, but at a time early enough to reverse damage to some or all of the affected tissue. Preferably, the agent is administered less than 12 hours, more preferably less than 6 hours and still more preferably less than about 3 hours after onset of the ischemic event. Treatment may be initiated before, during or after reperfusion of the ischemic tissue. In many instances, the time of reperfusion cannot be accurately determined, but it is preferred that treatment begin before, during or soon after reperfusion to prevent or lessen additional damaging consequences which may result from reperfusion.
- In the event of a clot inducing an ischemic episode, drugs such as TPA which break up the clot can be administered to reduce the potential tissue damage. Once dosed, the drug acts quickly to remove the vascular blockade and, therefore, the time at which the ischemic event ends can be determined. In one preferred embodiment, the inhibitor of NF-κB activation is administered at the same time or immediately following the clot dissolving drug.
- In certain other preferred embodiments, the inhibitor of NF-κB activation is administered prior to the onset of ischemia. The onset of ischemia can be predicted in the case of certain medical procedures, such as surgical procedures. In another preferred embodiment, the disclosed compound is administered just prior to or immediately following the release of ischemia and onset of reperfusion during such a medical procedure (e.g., angioplasty procedures).
- The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature.
- Methods
- Six male Sprague Dawley rats (300 g) were anesthetized with haloethane and subjected to middle cerebral artery (MCA) occlusion using a nylon filament for 2 h. Subsequently, the filament was removed and reperfusion of the infarcted tissue occurred for 24 hours before the rat was sacrificed.
- Staining of coronal sections (2.0 mm×7-8) with triphenyltetrazolium chloride (TTC) taken throughout the brain were evaluated under blinded conditions using image analysis to determine infarct size.
- The infarct was also expressed as a percentage of the contralateral (non-infarcted) hemisphere to provide an indication of how much of the ipsilateral (infarcted) hemisphere was actually damaged by the procedure. Because edema is present in the infarcted hemisphere, it is often impossible to directly ascertain the percentage of the ipsilateral hemisphere that has been damaged.
- Dosing Regimen
- Rats were given iv bolus injections (1.0 mL/kg) of either vehicle (10
% PEG 200/saline; n=3) or N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid (0.03 mg/kg; n=3) at 30 minutes, 2 hours, and 6 hours after the start of the occlusion. - Results
- Infarct volume was decreased by 62% on the ipsilateral hemisphere in treated animals (FIG. 1). This reflects a decrease in total damage of the hemisphere from 19% to 2% (FIG. 2).
- Methods
- Male Sprague Dawley rats (250-400 g) were anesthetized with haloethane and subjected to middle cerebral artery (MCA) occlusion using a nylon filament for 2 h. Subsequently, the filament was removed and reperfusion of the infarcted tissue occurred for 24 hours before the rat was sacrificed.
- Immediately after the filament was withdrawn, the animals were evaluated using a neurological scoring system. Neurological scores were expressed on a scale from 0 to 10, with 0 representing no neurological deficit and 10 representing severe neurological deficit. After 24 hours and before sacrifice, animals were evaluated a second time using the same neurological scoring system.
- Staining of coronal sections (2.0 mm×7-8) with triphenyltetrazolium chloride (TTC) taken throughout the brain were evaluated under blinded conditions using image analysis to determine infarct size.
- Dosing Regimen
- Rats were given iv bolus injections (1.0 mL/kg) of either vehicle (50% propylene glycol/saline; n=8) or 7-n-propyl-clasto-lactacystin β-lactone (0.1 mg/kg; n=6) at 2 hours after the start of the occlusion.
- Results
- In animals treated with 7-n-propyl-clasto-lactacystin β-lactone, infarct volume was decreased by 70% (FIG. 5).
- All animals had a neurological score of 10±0 immediately after the 2 hour ischemic episode. At 24 hours, the vehicle-treated rats had a mean score of 8.7±0.6, whereas rats treated with a single 0.1 mg/kg dose of 7-n-propyl-clasto-lactacystin β-lactone had a mean score of 5.5±1 (FIG. 6). These data represent a 40% neurological improvement for the drug-treated animals.
- Conclusion
- 7-n-propyl-clasto-lactacystin β-lactone provides significant protection in both the degree of neurological deficit and infarcted brain damage.
- Methods
- Male Sprague Dawley rats (250-400 g) were anesthetized with haloethane and subjected to middle cerebral artery (MCA) occlusion using a nylon filament for 2 h. Subsequently, the filament was removed and reperfusion of the infarcted tissue occurred for 24 hours before the rat was sacrificed.
- Immediately after the filament was withdrawn, the animals were evaluated using a neurological scoring system. Neurological scores were expressed on a scale from
pb 0 to 10, with 0 representing no neurological deficit and 10 representing severe neurological deficit. After 24 hours and before sacrifice, animals were evaluated a second time using the same neurological scoring system. - Staining of coronal sections (2.0 mm×7-8) with triphenyltetrazolium chloride (TTC) taken throughout the brain were evaluated under blinded conditions using image analysis to determine infarct size.
- Dosing Regimen
- Rats were given iv bolus injections (1.0 mL/kg) of either vehicle (50% propylene glycol/saline; n=8) or 7-n-propyl-clasto-lactacystin β-lactone (0.3 mg/kg; n=7) at 2 hours after the start of the occlusion. Two additional groups of rats were given iv bolus injections (1.0 mL/kg) of 7-n-propyl-clasto-lactacystin β-lactone at 0 minutes, 2 hours, and 6 hours after the start of the occlusion. One group (0.1 mg/kg×3; n=6) received 0.1 mg/kg at each of these times, while another group (0.3 mg/kg×3; n=7) received 0.3 mg/kg at each of the three timepoints.
- Results
- In animals treated with a single dose of 7-n-propyl-clasto-lactacystin β-lactone, infarct volume was decreased by 50% (FIG. 3). Infarct volume was not significantly decreased in either the 0.1 mg/kg×3 dosage group or the 0.3 mg/kg×3 dosage group (FIG. 7).
- All animals had a neurological score of 10±0 immediately after the 2 hour ischemic episode. At 24 hours, the vehicle-treated rats had a mean score of 8.7±0.6, whereas rats treated with a single 0.3 mg/kg dose of 7-n-propyl-clasto-lactacystin β-lactone had a mean score of 4±1 (FIG. 8). These data represent a 60% neurological improvement for the drug-treated animals. No significant improvement in neurological score was observed in either the 0.1 mg/kg×3 dosage group or the 0.3 mg/kg×3 dosage group (FIG. 8).
- Conclusion
- 7-n-propyl-clasto-lactacystin β-lactone provides significant protection in both the degree of neurological deficit and infarcted brain damage.
- Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention, which is defined by the following claims.
Claims (24)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/285,170 US6271199B2 (en) | 1997-02-15 | 1998-02-17 | Treatment of infarcts |
US09/919,116 US20010053760A1 (en) | 1997-02-15 | 2001-07-30 | Treatment of infarcts |
US10/118,526 US20030069189A1 (en) | 1997-02-15 | 2002-04-08 | Treatment of infarcts |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80193697A | 1997-02-15 | 1997-02-15 | |
US98833997A | 1997-12-03 | 1997-12-03 | |
US09/285,170 US6271199B2 (en) | 1997-02-15 | 1998-02-17 | Treatment of infarcts |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US98833997A Continuation-In-Part | 1997-02-15 | 1997-12-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/919,116 Continuation US20010053760A1 (en) | 1997-02-15 | 2001-07-30 | Treatment of infarcts |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010002391A1 true US20010002391A1 (en) | 2001-05-31 |
US6271199B2 US6271199B2 (en) | 2001-08-07 |
Family
ID=27122399
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/285,170 Expired - Lifetime US6271199B2 (en) | 1997-02-15 | 1998-02-17 | Treatment of infarcts |
US09/919,116 Abandoned US20010053760A1 (en) | 1997-02-15 | 2001-07-30 | Treatment of infarcts |
US10/118,526 Abandoned US20030069189A1 (en) | 1997-02-15 | 2002-04-08 | Treatment of infarcts |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/919,116 Abandoned US20010053760A1 (en) | 1997-02-15 | 2001-07-30 | Treatment of infarcts |
US10/118,526 Abandoned US20030069189A1 (en) | 1997-02-15 | 2002-04-08 | Treatment of infarcts |
Country Status (15)
Country | Link |
---|---|
US (3) | US6271199B2 (en) |
EP (1) | EP0979096B1 (en) |
JP (1) | JP2001511814A (en) |
CN (1) | CN1159061C (en) |
AT (1) | ATE240113T1 (en) |
AU (1) | AU741802B2 (en) |
CA (1) | CA2281224A1 (en) |
DE (1) | DE69814618T2 (en) |
ES (1) | ES2196547T3 (en) |
HK (1) | HK1025266A1 (en) |
IL (1) | IL131410A0 (en) |
NO (1) | NO321203B1 (en) |
NZ (1) | NZ337364A (en) |
PT (1) | PT979096E (en) |
WO (1) | WO1998035691A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050004164A1 (en) * | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
WO2005002572A2 (en) * | 2003-06-20 | 2005-01-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
WO2005080568A1 (en) * | 2004-02-20 | 2005-09-01 | Index Pharmaceuticals Ab | Methods and compositions for treatment or prevention of secondary ischemic injury |
US20060014831A1 (en) * | 2004-05-19 | 2006-01-19 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
US7144723B2 (en) | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US7276530B2 (en) | 2004-04-30 | 2007-10-02 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
US20080280968A1 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US20090036390A1 (en) * | 2004-12-03 | 2009-02-05 | Dana-Farber Cancer Institute | Compositions and methods for treating neoplastic diseases |
US20090156469A1 (en) * | 2007-12-07 | 2009-06-18 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating waldenstrom's macroglobulinemia |
US20090298906A1 (en) * | 2008-05-12 | 2009-12-03 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
US20090318529A1 (en) * | 2003-06-20 | 2009-12-24 | Fenical William H | Salinosporamides and methods for use thereof |
US20100144826A1 (en) * | 2002-06-24 | 2010-06-10 | The Regents Of The University Of California | Salinosporamides and Methods for Use Thereof |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890909B1 (en) * | 1997-07-04 | 2005-05-10 | Fujisawa Pharmaceutical Co., Ltd. | Brain-protective agent |
US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
US20090042807A1 (en) * | 1998-05-20 | 2009-02-12 | Nisar Ahmed Khan | Oligopeptide treatment of ischemia reperfusion injury |
EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
EP1223948A2 (en) * | 1999-09-13 | 2002-07-24 | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
EP1300418A1 (en) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
US6713459B1 (en) * | 2000-04-28 | 2004-03-30 | East Tennessee State University | Methods for the prophylactic and therapeutic treatment of cardiac tissue damage |
AU2002243646B2 (en) | 2001-01-25 | 2006-06-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
PT1392355E (en) | 2001-05-21 | 2007-03-30 | Alcon Inc | Use of proteasome inhibitors to treat dry eye disorders |
US7112588B2 (en) | 2001-05-21 | 2006-09-26 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
WO2003030823A2 (en) * | 2001-10-05 | 2003-04-17 | Combinatorx, Incorporated | Combinations for the treatment of immunoinflammatory disorders |
CN100358515C (en) * | 2001-12-10 | 2008-01-02 | 杜燕生 | Treatment of neurodegenerative and cardiovascular disorders |
US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US7517529B2 (en) | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
WO2005023187A2 (en) * | 2003-08-28 | 2005-03-17 | Kem David C | Inhibitor of cardiac tachyarrhythmias |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
EP1771194A2 (en) * | 2004-07-07 | 2007-04-11 | Biodevelops Pharma Entwicklung GmbH | Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface |
US20060008454A1 (en) * | 2004-07-07 | 2006-01-12 | Dr. Helmut Brunar | Use of a compound for enhancing the expression of membrane proteins on the cell surface |
EP1785431B1 (en) * | 2004-08-30 | 2016-01-20 | Toray Industries, Inc. | Fractionation apparatus |
WO2006062732A2 (en) * | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
JP4846799B2 (en) * | 2005-07-05 | 2011-12-28 | バイオテンプト ベー.フェー. | Tumor treatment |
US20090017006A1 (en) * | 2005-07-06 | 2009-01-15 | Biodevelops Pharma Entwicklung Gmbh | Use of a compound for enhancing the expression of membrane proteins on the cell surface |
US20070015777A1 (en) * | 2005-07-14 | 2007-01-18 | Myogen, Inc. | Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart |
US7691896B2 (en) * | 2005-08-10 | 2010-04-06 | President And Fellows Of Harvard College | Analogs of salinosporamide A |
EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
ES2293834B1 (en) * | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | COMPOSED WITH INHIBITING ACTIVITY OF UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS THERAPEUTIC APPLICATIONS. |
WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
SG178780A1 (en) * | 2007-02-12 | 2012-03-29 | Biotempt Bv | Treatment of trauma-hemorrhage with short oligopeptides |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
MX349769B (en) | 2008-06-17 | 2017-08-11 | Millennium Pharm Inc | Boronate ester compounds and pharmaceutical compositions thereof. |
AR075090A1 (en) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
JP5954728B2 (en) | 2010-01-22 | 2016-07-20 | 国立研究開発法人科学技術振興機構 | Probe reagent for measuring protein degradation activity |
EA029521B1 (en) | 2010-03-31 | 2018-04-30 | Милленниум Фармасьютикалз, Инк. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
SG10201603059YA (en) | 2012-05-09 | 2016-05-30 | Cantex Pharmaceuticals Inc | Treatment Of Myelosuppression |
WO2014170628A1 (en) | 2013-04-16 | 2014-10-23 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
WO2015117136A1 (en) | 2014-02-03 | 2015-08-06 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
JP2017524652A (en) | 2014-05-20 | 2017-08-31 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Boron-containing proteasome inhibitors for use after primary cancer therapy |
WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
JP2018510859A (en) | 2015-03-17 | 2018-04-19 | レオン−ナノドラッグズ ゲーエムベーハー | Nanoparticles containing stabilized boronic acid compounds |
EP3700567A4 (en) * | 2017-10-26 | 2021-09-29 | The Regents of The University of California | Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0518955A4 (en) | 1990-03-05 | 1993-09-22 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) * | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
EP0824918B1 (en) * | 1995-05-12 | 2007-03-28 | AnGes MG, Inc. | REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB |
US5942494A (en) | 1995-10-06 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70) |
BR9710408A (en) | 1996-03-19 | 1999-08-17 | Proscript Inc | Kinase capable of ikba specific silicon phosphorylation |
US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
-
1998
- 1998-02-17 NZ NZ337364A patent/NZ337364A/en unknown
- 1998-02-17 DE DE69814618T patent/DE69814618T2/en not_active Expired - Lifetime
- 1998-02-17 EP EP98906511A patent/EP0979096B1/en not_active Expired - Lifetime
- 1998-02-17 CA CA002281224A patent/CA2281224A1/en not_active Abandoned
- 1998-02-17 AT AT98906511T patent/ATE240113T1/en not_active IP Right Cessation
- 1998-02-17 ES ES98906511T patent/ES2196547T3/en not_active Expired - Lifetime
- 1998-02-17 CN CNB988033968A patent/CN1159061C/en not_active Expired - Fee Related
- 1998-02-17 JP JP53600398A patent/JP2001511814A/en not_active Ceased
- 1998-02-17 US US09/285,170 patent/US6271199B2/en not_active Expired - Lifetime
- 1998-02-17 AU AU61719/98A patent/AU741802B2/en not_active Ceased
- 1998-02-17 WO PCT/US1998/003077 patent/WO1998035691A1/en not_active Application Discontinuation
- 1998-02-17 IL IL13141098A patent/IL131410A0/en not_active IP Right Cessation
- 1998-02-17 PT PT98906511T patent/PT979096E/en unknown
-
1999
- 1999-08-16 NO NO19993935A patent/NO321203B1/en unknown
-
2000
- 2000-07-27 HK HK00104702A patent/HK1025266A1/en not_active IP Right Cessation
-
2001
- 2001-07-30 US US09/919,116 patent/US20010053760A1/en not_active Abandoned
-
2002
- 2002-04-08 US US10/118,526 patent/US20030069189A1/en not_active Abandoned
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080070273A1 (en) * | 2000-11-16 | 2008-03-20 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US7928138B2 (en) | 2000-11-16 | 2011-04-19 | Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US20090069401A1 (en) * | 2000-11-16 | 2009-03-12 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US20090197937A1 (en) * | 2000-11-16 | 2009-08-06 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US7879576B2 (en) | 2000-11-16 | 2011-02-01 | Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US7144723B2 (en) | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
US10912764B2 (en) | 2002-06-24 | 2021-02-09 | The Regents Of The University Of California | Salinosporamides and methods of use thereof |
US8637565B2 (en) | 2002-06-24 | 2014-01-28 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US9078881B2 (en) | 2002-06-24 | 2015-07-14 | The Regents Of The University Of California | Salinosporamides and methods of use thereof |
US9713607B2 (en) | 2002-06-24 | 2017-07-25 | The Regents Of The University Of California | Salinosporamides and methods of use thereof |
US8222289B2 (en) | 2002-06-24 | 2012-07-17 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US20100144826A1 (en) * | 2002-06-24 | 2010-06-10 | The Regents Of The University Of California | Salinosporamides and Methods for Use Thereof |
US10314818B2 (en) | 2002-06-24 | 2019-06-11 | The Regents Of The University Of California | Salinosporamides and methods of use thereof |
US20050004164A1 (en) * | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
US20090318529A1 (en) * | 2003-06-20 | 2009-12-24 | Fenical William H | Salinosporamides and methods for use thereof |
US8168803B2 (en) | 2003-06-20 | 2012-05-01 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
WO2005002572A2 (en) * | 2003-06-20 | 2005-01-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
US20050049294A1 (en) * | 2003-06-20 | 2005-03-03 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
WO2005002572A3 (en) * | 2003-06-20 | 2005-05-12 | Nereus Pharmaceuticals Inc | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
US20090182027A1 (en) * | 2003-06-20 | 2009-07-16 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US8217072B2 (en) | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
WO2005080568A1 (en) * | 2004-02-20 | 2005-09-01 | Index Pharmaceuticals Ab | Methods and compositions for treatment or prevention of secondary ischemic injury |
US20070298021A1 (en) * | 2004-02-20 | 2007-12-27 | Index Pharmaceuticals Ab | Methods and Compositions for the Treatment or Prevention of Secondary Ischemic Injury |
US7276530B2 (en) | 2004-04-30 | 2007-10-02 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
US7425580B2 (en) | 2004-05-19 | 2008-09-16 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
US20060014831A1 (en) * | 2004-05-19 | 2006-01-19 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
US8722724B2 (en) | 2004-12-03 | 2014-05-13 | Triphase Research And Development I Corp. | Compositions and methods for treating neoplastic diseases |
US20090036390A1 (en) * | 2004-12-03 | 2009-02-05 | Dana-Farber Cancer Institute | Compositions and methods for treating neoplastic diseases |
US10610517B2 (en) | 2004-12-03 | 2020-04-07 | Celgene International Ii Sàrl | Compositions and methods for treating neoplastic diseases |
US20080280968A1 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
US20090156469A1 (en) * | 2007-12-07 | 2009-06-18 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating waldenstrom's macroglobulinemia |
US20110172285A1 (en) * | 2008-05-12 | 2011-07-14 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
US7910616B2 (en) | 2008-05-12 | 2011-03-22 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
US8227503B2 (en) | 2008-05-12 | 2012-07-24 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
US8389564B2 (en) | 2008-05-12 | 2013-03-05 | Venkat Rami Reddy Macherla | Proteasome inhibitors |
US20090298906A1 (en) * | 2008-05-12 | 2009-12-03 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU6171998A (en) | 1998-09-08 |
NO993935D0 (en) | 1999-08-16 |
NO321203B1 (en) | 2006-04-03 |
EP0979096A1 (en) | 2000-02-16 |
IL131410A0 (en) | 2001-01-28 |
CN1159061C (en) | 2004-07-28 |
ES2196547T3 (en) | 2003-12-16 |
AU741802B2 (en) | 2001-12-13 |
NO993935L (en) | 1999-10-04 |
US20030069189A1 (en) | 2003-04-10 |
DE69814618D1 (en) | 2003-06-18 |
HK1025266A1 (en) | 2000-11-10 |
DE69814618T2 (en) | 2004-03-25 |
CN1250376A (en) | 2000-04-12 |
US20010053760A1 (en) | 2001-12-20 |
US6271199B2 (en) | 2001-08-07 |
CA2281224A1 (en) | 1998-08-20 |
JP2001511814A (en) | 2001-08-14 |
NZ337364A (en) | 2001-06-29 |
PT979096E (en) | 2003-09-30 |
ATE240113T1 (en) | 2003-05-15 |
EP0979096B1 (en) | 2003-05-14 |
WO1998035691A1 (en) | 1998-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6271199B2 (en) | Treatment of infarcts | |
WO1998035691A9 (en) | Treatment of infarcts through inhibition of nf-kappab | |
Levi et al. | The cytokine‐mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia | |
Gori et al. | Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration | |
de Leciñana et al. | Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke | |
RU2166326C2 (en) | Combination of thrombolytically active proteins and anticoagulants | |
EP0702551A1 (en) | Compositions and methods for reparation and prevention of fibrotic lesions | |
Shihab et al. | Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-β1 in chronic cyclosporine nephrotoxicity | |
JP4077030B2 (en) | Method for reducing myocardial injury during acute myocardial infarction | |
KR100701539B1 (en) | New Use of Melagatran | |
Philp et al. | Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis | |
Laurer et al. | Pharmacologic therapy in traumatic brain injury: update on experimental treatment strategies | |
Hashimoto et al. | Treatment of Behçet's disease | |
US7786170B2 (en) | Histone deacetylase inhibitor enhancement of trail-induced apoptosis | |
EP1372702B1 (en) | Treatment of hypoxia/ischaemia related blood flow resistance using beta-interferon | |
MXPA99007509A (en) | Treatment of infarcts through inhibition of nf-kappab | |
Lai et al. | Efficacy of albendazole–GM6001 co-therapy against Angiostrongylus cantonensis-induced meningitis in BALB/c mice | |
JP5427336B2 (en) | Composition for the treatment and prevention of necrosis | |
CA2297464A1 (en) | Pharmaceutical preparation for the treatment of inflammatory processes | |
US6395772B1 (en) | Method for blocking endothelial cell-leukocyte attachment by inhibiting expression of adhesion molecules on the vascular endothelium for therapeutic applications | |
Saglam et al. | The effect of captopril on brain apoptosis after burn injury in rats | |
AU2004220717B2 (en) | Pharmaceutical preparation for the treatment of inflammatory processes | |
Van der Flier et al. | Anti-inflammatory adjuvant agents in bacterial meningitis | |
Flier et al. | Anti-inflammatory adjuvant agents in bacterial meningitis | |
Bazan et al. | Delayed Maturation of Cortical Infarction: Role of Caspasesand NF-K B-Mediated Transcription |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PROSCRIPT, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRAND, STEPHEN;GOLDBERG, ALFRED L.;PLAMONDON, LOUIS;AND OTHERS;REEL/FRAME:010108/0418;SIGNING DATES FROM 19990607 TO 19990630 |
|
AS | Assignment |
Owner name: LEUKOSITE, INC., MASSACHUSETTS Free format text: MERGER;ASSIGNOR:PROSCRIPT, INC.;REEL/FRAME:011175/0413 Effective date: 20000315 Owner name: MILLENNIUM PARMACEUTICALS, INC., MASSACHUSETTS Free format text: MERGER;ASSIGNOR:LEUKOSITE, INC.;REEL/FRAME:011175/0417 Effective date: 20000315 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: PROSCRIPT, INC., MASSACHUSETTS Free format text: RERECORD TO REMOVE 08/988,333 , REEL 010108, FRAME 0418;ASSIGNORS:BRAND, STEPHEN;GOLDBERG, ALFRED L.;PLAMONDON, LOUIS;AND OTHERS;SIGNING DATES FROM 19990607 TO 19990630;REEL/FRAME:026691/0218 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |